Natera, Inc.
NTRA
Peringkat dalam Saham
#408
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Harga Saham
$409.59
Kapitalisasi Pasar
$59.04B
Perubahan (1 hari)
2.55%
Perubahan (1 tahun)
117.17%
Negara
US
Perdagangan Natera, Inc. (NTRA)
Kategori
Healthcare
Laba untuk Natera, Inc. (NTRA)
Laba pada Jun 2026 TTM: $-252.70M
Menurut laporan keuangan terbaru dari Natera, Inc., laba saat ini perusahaan adalah $-252.70M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-434.53M, peningkatan dibandingkan laba tahun 2022 sebesar $-546.82M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Natera, Inc. dari 2012 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-252.70M | 33.19% |
| 2024 | $-189.73M | -56.34% |
| 2023 | $-434.53M | -20.54% |
| 2022 | $-546.82M | 16.07% |
| 2021 | $-471.10M | 105.14% |
| 2020 | $-229.65M | 86.96% |
| 2019 | $-122.83M | -3.92% |
| 2018 | $-127.83M | -5.91% |
| 2017 | $-135.86M | 42.08% |
| 2016 | $-95.62M | 36.07% |
| 2015 | $-70.28M | 1,264.03% |
| 2014 | $-5.15M | -86.12% |
| 2013 | $-37.11M | -51.28% |
| 2012 | $-76.17M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $7.61B | -3,111.07% |
US
|
|
| $4.76B | -1,984.44% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -756.11% |
US
|
|
| $1.61B | -736.72% |
US
|
